Group 1 - The core focus events for Dize Pharmaceutical in 2026 and beyond include the progress of H-share listing, key milestones in the R&D pipeline, annual business plan review, and commercialization and market expansion [1] - Dize Pharmaceutical submitted its H-share listing application to the Hong Kong Stock Exchange on January 23, 2026, aiming for a dual listing in Hong Kong to enhance its global strategy and attract international investors [2] - The company plans to advance multiple core products into clinical data update stages in 2026, including the global multi-center Phase III study of Shuwotai (Shuwotai) for EGFR Exon20ins non-small cell lung cancer, which has completed patient enrollment [3] Group 2 - Dize Pharmaceutical plans to hold a board meeting in 2026 to review the annual sales plan, which is yet to be finalized and will be disclosed after board approval [4] - The company aims to leverage the inclusion of core products Shuwotai and Guaizhe in the national medical insurance catalog to deepen domestic market coverage and promote overseas commercialization in 2026 [5] - The sales expense ratio decreased to 72% in the first three quarters of 2025, and the company plans to further enhance operational efficiency in 2026 [5]

Core Viewpoint - Tianyao Pharmaceutical (600488) reported a significant decline in revenue for 2024, with total revenue of 3.215 billion yuan, a decrease of 15% year-on-year, while net profit attributable to shareholders increased by 14.01% to 133 million yuan due to a substantial reduction in sales expenses [1][2] Financial Performance - The company's sales expenses dropped from 1.051 billion yuan in 2023 to 570 million yuan in 2024, nearly halving, attributed to optimized sales models and improved efficiency in expense usage [1] - The gross profit margin was 45.45%, a decrease of 2.11% year-on-year, and operating cash flow decreased by 214 million yuan to 569 million yuan [2] - The weighted return on equity increased by 0.5 percentage points to 4.45% [2] Business Segment Performance - Revenue from core business segments declined, with steroid hormones generating 1.732 billion yuan (down 16.89%), amino acids at 296 million yuan (down 19.32%), and other formulations at 1.161 billion yuan (down 10.67%) [2] Executive Compensation - Despite the revenue decline, executive compensation increased significantly, with two executives earning over 1 million yuan; the vice president's salary rose to 1.976 million yuan, an increase of 1.638 million yuan, and the CEO's salary increased to 1.4346 million yuan, up by 1.284 million yuan [2] Shareholder Activity - In the fourth quarter of 2024, northbound funds significantly reduced their holdings in Tianyao Pharmaceutical, with a total of 15.6944 million shares, a decrease of 2.1127 million shares, representing an 11.86% decline [3]